CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis

American Journal of Pathology

Volumn 177, Issue 3, 2010, Pages 1244-1254

  Maltby, Steven ^a   Wohlfarth, Carolin ^a   Gold, Matthew ^a   Zbytnuik, Lori ^a   Hughes, Michael R ^a   McNagny, Kelly M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CINTREDEKIN BESUDOTOX; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SIALOMUCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CHIMERA; COLON HEMORRHAGE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; EOSINOPHIL; EOSINOPHILIA; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MAST CELL; MEDIATOR RELEASE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ULCERATIVE COLITIS; WEIGHT REDUCTION;

EID: 77956516292     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100191     Document Type: Article

References (39)

1. Hendrickson BA, Gokhale R, Cho JH: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002, 15:79-94
2. Torres MI, Rios A: Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol 2008, 14:1972-1980
3. Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, Maschek H, Stolte M, Gebel M, Manns MP: Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996, 28:1-13
4. Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, de Freitas FC, Lapa e Silva JR: Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol 2003, 36:120-125
5. Makiyama K, Kanzaki S, Yamasaki K, Zea-Iriarte W, Tsuji Y: Activation of eosinophils in the pathophysiology of ulcerative colitis. J Gastroenterol 1995, 30 Suppl 8:64-69
6. Chen W, Paulus B, Shu D, Wilson, Chadwick V: Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol 2001, 36:515-520
7. Lampinen M, Carlson M, Sangfelt P, Taha Y, Thorn M, Loof L, Raab Y, Venge P: IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001, 46:2004-2009
8. Carlson M, Raab Y, Peterson C, Hallgren R, Venge P: Increased intraluminal release of eosinophil granule proteins EPO. ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999, 94:1876-1883
9. Sangfelt P, Carlson M, Thorn M, Loof L, Raab Y: Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 2001, 96:1085-1090
10. Bischoff SC, Mayer J, Nguyen QT, Stolte M, Manns MP: Immunohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999, 94:3521-3529
11. Powell N, Walker MM, Talley NJ: Gastrointestinal eosinophils in health, disease and functional disorders. Nat Rev Gastroenterol Hepatol 2010, 7:146-156
12. Ahrens R, Waddell A, Seidu L, Blanchard C, Carey R, Forbes E, Lampinen M, Wilson T, Cohen E, Stringer K, Ballard E, Munitz A, Xu H, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP: Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol 2008, 181:7390-7399
13. Forbes E, Murase T, Yang M, Matthaei KI, Lee JJ, Lee NA, Foster PS, Hogan SP: Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol 2004, 172:5664-5675
14. Forbes E, Hulett M, Ahrens R, Wagner N, Smart V, Matthaei KI, Brandt EB, Dent LA, Rothenberg ME, Tang M, Foster PS, Hogan SP: ICAM-CD34 1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol 2006, 80:330-341
15. Shichijo K, Makiyama K, Wen CY, Matsuu M, Nakayama T, Nakashima M, Ihara M, Sekine I: Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats. World J Gastroenterol 2005, 11:4505-4510
16. Vieira AT, Fagundes CT, Alessandri AL, Castor MG, Guabiraba R, Borges VO, Silveira KD, Vieira EL, Goncalves JL, Silva TA, Deruaz M, Proudfoot AE, Sousa LP, Teixeira MM: Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol 2009, 175:2382-2391
17. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI: IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24
18. Stevceva L, Pavli P, Husband A, Matthaei KI, Young IG, Doe WF: Eosinophilia is attenuated in experimental colitis induced in IL-5 deficient mice. Genes Immun 2000, 1:213-218
19. Beauchamp JR, Heslop L, Yu DS, Tajbakhsh S, Kelly RG, Wernig A, Buckingham ME, Partridge TA, Zammit PS: Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J Cell Biol 2000, 151:1221-1234
20. Joe AW, Yi L, Natarajan A, Le Grand F, So L, Wang J, Rudnicki MA, Rossi FM: Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 2010, 12:153-163
21. Trempus CS, Morris RJ, Bortner CD, Cotsarelis G, Faircloth RS, Reece JM, Tennant RW: Enrichment for living murine keratinocytes from the hair follicle bulge with the cell surface marker CD34. J Invest Dermatol 2003, 120:501-511
22. Baumheter S, Singer MS, Henzel W, Hemmerich S, Renz M, Rosen SD, Lasky LA: Binding of L-selectin to the vascular sialomucin CD34. Science 1993, 262:436-438
23. Baumhueter S, Dybdal N, Kyle C, Lasky LA: Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. Blood 1994, 84:2554-2565
24. Nielsen JS, McNagny KM: Novel functions of the CD34 family. J Cell Sci 2008, 121:3683-3692
25. Drew E, Merkens H, Chelliah S, Doyonnas R, McNagny KM: CD34 is a specific marker of mature murine mast cells. Exp Hematol 2002, 30:1211-1218
26. Radinger M, Johansson AK, Sitkauskiene B, Sjostrand M, Lotvall J: Eotaxin-2 regulates newly produced and CD34 airway eosinophils after allergen exposure. J Allergy Clin Immunol 2004, 113:1109-1116
27. Blanchet MR, Maltby S, Haddon DJ, Merkens H, Zbytnuik L, McNagny KM: CD34 facilitates the development of allergic asthma. Blood 2007, 110:2005-2012
28. Drew E, Merzaban JS, Seo W, Ziltener HJ, McNagny KM: CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution. Immunity 2005, 22:43-57
29. Nielsen JS, McNagny KM: Influence of host irradiation on long-term engraftment by CD34-deficient hematopoietic stem cells. Blood 2007, 110:1076-1077
30. Suzuki A, Andrew DP, Gonzalo JA, Fukumoto M, Spellberg J, Hashiyama M, Takimoto H, Gerwin N, Webb I, Molineux G, Amakawa R, Tada Y, Wakeham A, Brown J, McNiece I, Ley K, Butcher EC, Suda T, Gutierrez-Ramos JC, Mak TW: CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein. Blood 1996, 87:3550-3562
31. Lee NA, McGarry MP, Larson KA, Horton MA, Kristensen AB, Lee JJ: Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. J Immunol 1997, 158:1332-1344
32. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702
33. Cooper HS, Murthy SN, Shah RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69:238-249
34. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M, Li X: Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009, 15:341-352
35. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO: Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994, 107:1643-1652
36. Kitajima S, Takuma S, Morimoto M: Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999, 48:137-143
37. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, Gross V, Falk W: Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997, 107:353-358
38. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135
39. Pender SL, Chance V, Whiting CV, Buckley M, Edwards M, Pettipher R, MacDonald TT: Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model. Gut 2005, 54:1114-1120